Wildcat Capital Management’s Silexion Therapeutics SLXN Stock Holding History

Wildcat Capital Management’s Portfolio SLXN Stock Details SLXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-756	Closed	-$91.9K	–	7
2025 Q2	$91.9K	Hold	756	–	–	0.05%	6
2025 Q1	$125K	Hold	756	–	–	0.07%	8
2024 Q4	$228K	Hold	756	–	–	0.09%	8
2024 Q3	$536K	Buy	+756	New	+$1.19M	0.26%	7

Other funds holding SLXN

Montag & Associates Atlanta, Georgia $2.15B AUM 20.86% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Pflug Koory Omaha, Nebraska $250M AUM 42.29% 1-Year Est. Return

Wildcat Capital Management's SLXN Position: Q3 2025 in Review

Wildcat Capital Management sold out of Silexion Therapeutics (SLXN) in Q3 2025, closing a stake of 756 shares — an estimated $91.9K sold.

Wildcat Capital Management first reported a position in SLXN in Q3 2024 and held it in 4 quarters. The position peaked at $536K in Q3 2024. 4 funds tracked by Wall St. Rank hold SLXN as of Q3 2025.

Wildcat Capital Management reported no remaining Silexion Therapeutics position as of Q3 2025 after selling out during the quarter.
Wildcat Capital Management sold 756 Silexion Therapeutics shares in Q3 2025, an estimated $91.9K.
Wildcat Capital Management first reported a position in Silexion Therapeutics in Q3 2024 and held it in 4 quarters.
Wildcat Capital Management's Silexion Therapeutics position peaked at $536K in Q3 2024.
4 funds tracked by Wall St. Rank held Silexion Therapeutics as of Q3 2025.

Based on Wildcat Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.